April 20, 2024

High Stakes: Seven Key Drug Trial Failures in 2024

The cost of developing a new drug – a process that can take between 10 and 15 years from concept to market – has risen to approximately $2.3 billion, and there are many opportunities for failure along the way. Around 90% of drug candidates in clinical trials fail, despite significant investments in time and money. [Read More]
American Express
April 19, 2024

PRISM Market Moves on Friday: Paramount Global Jumps on Acquisition Reports, AMEX Gains; Netflix and Pure Storage Slide

US equities are mixed on Friday at midday after the S&P 500 and Nasdaq reversed earlier gains, and remain on pace for a sixth consecutive day of declines. Underperformers include entertainment, coatings, semis, HPCs, beauty, pharma, and construction materials, while it’s a stronger day for credit cards, casinos, airlines, media, oil majors, pipelines, and managed… [Read More]
Dr and Female patient
April 19, 2024

Aspira Women’s Health Secures New Agreement with Anthem Blue Cross, CA

Texas-based diagnostic tools company, Aspira Women’s Health (Nasdaq: AWH), has entered into a new agreement with Anthem Blue Cross in California for reimbursement coverage of the Company’s OvaSuiteSM portfolio of risk assessment tests effective June 1, 2024. Aspira’s OvaWatch® and Ova1Plus® provide the only comprehensive portfolio of blood tests to aid in the detection of… [Read More]
April 19, 2024

Positive Results for Lipocine in Obesity Study

Biopharmaceutical company, Lipocine Inc. (Nasdaq: LPCN) has announced positive results from a Phase 2 clinical trial evaluating LPCN 2401 for improving body composition by gaining lean mass and reducing fat mass. Lipocine believes that LPCN 2401 has potential as an adjunct therapy to GLP-1/GIP agonists. Drugs such as Wegovy®, tirzepatide, and Zepbound® are widely used… [Read More]
April 19, 2024

Moleculin Granted EMA Orphan Drug Designation for Leukemia Drug

Pharmaceutical company, Moleculin Biotech (Nasdaq: MBRX) has been granted Orphan Drug Designation for Annamycin in the treatment of acute myeloid leukemia (AML) by the European Medicines Agency (EMA). The company’s share price rose 6.31% following the news on Thursday. Anthracyclines, which have been an integral component of induction chemotherapy for AML for more than 30… [Read More]
April 18, 2024

Disappointment for Sage Therapeutics as Parkinson’s Disease Trial Misses Endpoint

In a crushing disappointment for Sage Therapeutics (Nasdaq: SAGE) and the Parkinson’s disease community, the company reported on Wednesday that its double-blind, placebo-controlled Phase 2 study of dalzanemdor (SAGE-718) in Parkinson’s Disease (PD) did not meet its primary endpoint. Sage’s shares rallied +4.30% in intraday trading on Thursday after a difficult day on Wednesday. Based… [Read More]
April 18, 2024

CorMedix Catheter Infection Treatment Commercially Available in US

CorMedix Inc. (Nasdaq: CRMD) has announced that its DefenCath® (taurolidine and heparin) catheter lock solution (CLS) is now commercially available for inpatient use in the US. DefenCath® has received FDA approval for use in reducing the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure receiving chronic hemodialysis through a central venous… [Read More]
April 18, 2024

Bond Markets Dip Amid Persistent Rate Hike Speculations: Markets Summary

The world’s largest bond market witnessed further declines this month as solid economic indicators and assertive comments from Federal Reserve officials bolstered the belief that interest rates may remain elevated longer than expected. U.S. Treasury yields experienced a drop across the curve, with two-year yields nearing the 5% threshold. Federal Reserve Bank of New York… [Read More]